Elite Athletes Diagnosed and Treated for Diabetes May Reduce Heart Failure

Published Date: 08 Mar 2023

95% of athletes are diagnosed and treated for non-invasive heart disease, such as heart attacks or seizures, or implantable cardioverter defibrillator (ICD) shock.

Read Full News

Latest News

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

Expert Consensus on Knowledge Gaps in Dermatology for Skin of Color, With Henry Lim, MD Henry Lim, MD

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Latest News

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Updated Urticaria Guidelines Clarify Diagnosis, Biomarkers, Treatment Pathways

6 Dermatology Headlines You Missed in January 2026

Bimekizumab Demonstrates Long Term Efficacy in Hidradenitis Suppurativa

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo

News All Time

Practical Approaches to Hyperpigmentation and Hypopigmentation, With Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

This segment of the latest Skin of Color Savvy episode highlights a conversation between Nada Elbuluk, MD, MSc, and Michelle Rodrigues, MBBS.

Skin of Color Savvy: Highlights from 2025 Tim Smith

In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.

Skin of Color Savvy: On-Site Interviews at the Meeting the Challenge Summit Angel S. Byrd, MD, PhD, Valerie D. Callender, MD, Valerie Harvey, MD, MPH, Stafford Brown, MD, MBA

This episode of Skin of Color Savvy was filmed on-site at the Skin of Color Society's 'Meeting the Challenge Summit' in Washington, DC.

Skin of Color Savvy: Highlights From the Most-Watched Episodes of 2025 Andrew F Alexis, MD, MPH, Shawn Kwatra, MD, Crystal Aguh, MD, FAAD, John E. Harris, MD, PhD, Nada Elbuluk, MD, MSc, Michelle Rodrigues, MBBS

This new episode from January 2026 features a compilation of 3 clips from the most viewed episodes of 2025.

Maui Derm 2026 Presentation Highlights Icotrokinra, Other New Dermatology Drugs

Maui Derm 2026 Presentation Highlights Icotrokinra, Other New Dermatology Drugs

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

LEVEL UP: New Data on Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

LEVEL UP: New Data on Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

Personalized Care Improvements Identified for Older Patients with Skin Cancer

Personalized Care Improvements Identified for Older Patients with Skin Cancer

What to Expect at the 2026 Maui Derm Conference

What to Expect at the 2026 Maui Derm Conference

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Melanoma Surgery Delay After 4 Weeks Post-Diagnosis Decreases Survival Rates

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

Ritlecitinib Efficacious for Non-Segmental Vitiligo Across Various Subgroups

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

ICP-332 Effective, Safe for Treating Moderate to Severe Atopic Dermatitis

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Unmet Needs Highlighted Regarding CSU Treatment Escalation

Recommended News For You

Pressing the Sleep button could have a positive impact on cognition.

New therapeutic strategies raised to prevent and resist metastasis in lymph nodes of breast cancer

Exercise may help breast cancer survivors manage weight

When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

The White House has postponed its plan to outlaw menthol cigarettes indefinitely.

Recommended Articles For You

Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment 

How to Manage Dic with the Right Treatment Approach 

The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology 

Circulating Tumor Cells & Platelet Interactions: Crosstalk for Therapeutic Advances 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

2.

Tumor-targeting fluorescent bacteria illuminate cancer for precision surgery

3.

Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation

4.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

5.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

1.

The Precision Revolution: Bispecific Antibodies and Antibody-Drug Conjugates Reshaping the Oncology Landscape

2.

Understanding the Causes and Symptoms of Cavernous Sinus Thrombosis 

3.

Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics

4.

Gender-Specific Dual Antiplatelet Therapy Strategies for Women After PCI

5.

A New Perspective on Spherocytosis: Uncovering Innovative Treatments

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Role of Nimotuzumab in Management of Nasopharyngeal Cancer

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

3.

Thromboprophylaxis In Medical Settings

4.

"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC

5.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot